Holen Sie sich die Stockscreener-App
29.16
0.14%
-0.04
Vorhandelsmarkt:
29.20
0.04
+0.14%
Schlusskurs vom Vortag:
$29.20
Offen:
$29.51
24-Stunden-Volumen:
172.42K
Relative Volume:
0.72
Marktkapitalisierung:
$820.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-5.2097
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+3.50%
1M Leistung:
-1.22%
6M Leistung:
-21.97%
1J Leistung:
+90.71%
1-Tages-Spanne:
$28.46
$29.88
1-Wochen-Bereich:
$28.14
$30.14
52-Wochen-Spanne:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
29.16 | 827.50M | 0 | -69.47M | -73.92M | -5.5973 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Deutsche Bank AG Purchases 4,370 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Holdings Boosted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Holdings Decreased by Ameriprise Financial Inc. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Analysts - Defense World
LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks
7,447 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by D. E. Shaw & Co. Inc. - Defense World
LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision - Investing.com Canada
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Northern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com
Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN
Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Tower Research Capital LLC TRC Has $54,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia
LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - Yahoo Finance
Raymond James Financial Inc. Takes $245,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Leerink Partnrs Analysts Raise Earnings Estimates for LENZ - Defense World
HC Wainwright Issues Negative Estimate for LENZ Earnings - Defense World
Leerink Partnrs Has Negative Outlook of LENZ FY2028 Earnings - Defense World
LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Positive Estimate for LENZ FY2029 Earnings - Defense World
Lenz Therapeutics inks $125M licensing deal with Lotus - Axios
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by Wells Fargo & Company MN - Defense World
LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia - marketscreener.com
LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - The Manila Times
Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of “Buy” by Brokerages - Defense World
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Market Recap Check: LENZ Therapeutics Inc (LENZ)’s Negative Finish at 25.89, Up/Down -11.03 - DWinneX
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times
LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq
First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan
Barclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Legal & General Group Plc Has $252,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 - The Manila Times
LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq
Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan
Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail
ProfittoPath - TradingView
LENZ Therapeutics Inc (LENZ)’s stock chart: A technical perspective - uspostnews.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Notable Wednesday Option Activity: LENZ, CVNA, APPN - Nasdaq
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Alliancebernstein L.P. - Defense World
13,280 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Alliancebernstein L.P. - Defense World
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):